March 23, 2017 Vaccibody AS announces vaccination of first patient in its phase IIa study with VB10.16 immunotherapy for patients with HPV16 induced high grade lesions of the cervix
Vaccibody AS announced today vaccination of the first patient in its phase IIa study – an exploratory, open-label, multicenter study with VB10.16 immunotherapy for the treatment of high grade Cervical Intraepithelial Neoplasia (CIN 2/3) caused by human papillomavirus 16 (HPV 16). The phase I part of...